In patients with recent-onset type 2 diabetes, subcutaneous injection of exenatide immediately prior to meal consumption (5,384 kJ) significantly reduces serum insulin at 2, 4, 6, and 8 h post-meal (Schwartz et al., 2010). This evidence concerns the gene INS and type 2 diabetes mellitus.